MiMedx Group Inc (MDXG)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $468.42M
Last updated: Nov 17, 2026 at 11:05 AM ET
MiMedx Group Inc (MDXG) Stock Forecast
Analysts expect MiMedx Group (MDXG) to earn -$0.09 per share in the fiscal year ending Dec 31, 2026, on revenue of $256.63M. Of 5 analysts, 5 rate the stock Buy or Strong Buy, 0 Hold and 0 Sell or Strong Sell, for a consensus of Buy. Over the last 30 days, 0 estimates for the fiscal year ending Dec 31, 2026 were revised up and 1 down.
Analyst Ratings
Scoring Strong Buy as 1 and Strong Sell as 5, the 5 ratings average 1.80, inside the Buy band from 1.5 up to 2.5. Buy and Strong Buy make up 100% of the ratings.
| Rating | Analysts | Share |
|---|---|---|
| Strong Buy | 1 | 20.0% |
| Buy | 4 | 80.0% |
| Hold | 0 | 0.0% |
| Sell | 0 | 0.0% |
| Strong Sell | 0 | 0.0% |
- Consensus
- Buy
- Total analysts
- 5
Price Target
Analyst price targets are part of paid GNG plans. See plans
Annual Estimates
From the first fiscal year below to the second, the EPS consensus turns from a loss to a profit and revenue estimates rise 13.8%.
- Fiscal year ending Dec 31, 2026
- -$0.09
- EPS consensus, revenue $256.63M
- Fiscal year ending Dec 31, 2027
- $0.11
- EPS consensus, revenue $292.07M
- Next report
- Feb 23, 2027
- Estimated
EPS range
Revenue range
| Fiscal year ending | EPS consensus | EPS range | EPS analysts | Revenue consensus | Revenue range | Rev. analysts |
|---|---|---|---|---|---|---|
| Dec 31, 2026 | -$0.09 | -$0.10 to -$0.08 | 3 | $256.63M | $250.50M to $270.00M | 4 |
| Dec 31, 2027 | $0.11 | $0.04 to $0.17 | 3 | $292.07M | $279.50M to $308.60M | 4 |
Quarterly Estimates
The EPS consensus rises from -$0.03 for the quarter ending Dec 31, 2026 to $0.01 for the quarter ending Mar 31, 2027.
EPS range
Revenue range
| Quarter ending | EPS consensus | EPS range | EPS analysts | Revenue consensus | Revenue range | Rev. analysts |
|---|---|---|---|---|---|---|
| Dec 31, 2026 | -$0.03 | -$0.03 to -$0.03 | 7 | $67.86M | $63.60M to $70.77M | 7 |
| Mar 31, 2027 | $0.01 | $0.01 to $0.01 | 2 | $65.47M | $62.90M to $69.00M | 4 |
Estimate Revisions
Across the 3 periods below, the last 30 days brought 0 upward and 1 downward EPS revisions.
| Period | Up 30 days | Down 30 days |
|---|---|---|
| Fiscal year ending Dec 31, 2026 | 0 | 1 |
| Fiscal year ending Dec 31, 2027 | 0 | 0 |
| Quarter ending Mar 31, 2027 | 0 | 0 |
EPS Trend
Over the last 90 days, the EPS consensus for the fiscal year ending Dec 31, 2026 has worsened from -$0.05.
| Period | Now | 7 days ago | 30 days ago | 60 days ago | 90 days ago | Change |
|---|---|---|---|---|---|---|
| Fiscal year ending Dec 31, 2026 | -$0.09 | -$0.08 | -$0.06 | -$0.05 | -$0.05 | N/A |
| Fiscal year ending Dec 31, 2027 | $0.11 | $0.11 | $0.11 | $0.11 | $0.17 | -38.4% |
| Quarter ending Mar 31, 2027 | $0.01 | $0.03 | $0.04 | $0.04 | $0.04 | -75.0% |
Frequently Asked Questions About MDXG
What is the MDXG stock forecast?
Consensus analyst estimates put MiMedx Group's EPS at -$0.09 for the fiscal year ending Dec 31, 2026, on revenue of $256.63M. The consensus rating from 5 analysts is Buy.
How do analysts rate MDXG stock?
Of 5 analysts covering MiMedx Group, 1 rates it Strong Buy, 4 Buy, 0 Hold, 0 Sell and 0 Strong Sell, for a consensus of Buy.
What EPS do analysts expect from MDXG next year?
For the fiscal year ending Dec 31, 2026, the consensus EPS estimate is -$0.09, with estimates from -$0.10 to -$0.08 from 3 analysts. For the fiscal year ending Dec 31, 2027, the consensus EPS estimate is $0.11, with estimates from $0.04 to $0.17 from 3 analysts.
What revenue do analysts expect from MiMedx Group next year?
For the fiscal year ending Dec 31, 2026, the consensus revenue estimate is $256.63M, with estimates from $250.50M to $270.00M. For the fiscal year ending Dec 31, 2027, the consensus revenue estimate is $292.07M, with estimates from $279.50M to $308.60M.
How many analysts cover MDXG?
5 analysts rate MiMedx Group stock, and 3 analysts estimate its EPS for the fiscal year ending Dec 31, 2026.
MDXG pages: Overview, Earnings, Forecast, Financials, Valuation, Competitors